{"nctId":"NCT04209400","briefTitle":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®","startDateStruct":{"date":"2014-04-18","type":"ACTUAL"},"conditions":["Hepatitis B"],"count":100,"armGroups":[{"label":"Sci-B-Vac®","type":"EXPERIMENTAL","interventionNames":["Biological: Sci-B-Vac®"]},{"label":"Engerix-B®","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Engerix-B®"]}],"interventions":[{"name":"Sci-B-Vac®","otherNames":[]},{"name":"Engerix-B®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Availability of written Informed Consent to participate in the study from the subject.\n2. Male or female between 18 and 45 years old without previous contact with hepatitis B virus (HBV).\n3. Good health condition based on full physical examination.\n4. Normal values of laboratory biochemical blood tests.\n5. Seronegative with respect to anti-HBs (surface) antibodies, anti-HBc (core) antibodies, and HBs Antigen (HBsAg) on screening.\n6. Not pregnant and not breast-feeding.\n7. For men and women of reproductive age: consent for use of an effective contraception method, for example, an intrauterine device, oral contraceptive, hypodermic implant or double barrier method (a condom with contraceptive sponge or contraceptive suppository) throughout the entire study.\n\nExclusion Criteria:\n\n1. Congenital or inherited immunodeficiency disorder in family history.\n2. Information of a serious blood disorder, cardiac disorder, or tumour.\n3. Current use of any medication that could alter immune reactivity.\n4. Infection with HBV at the present time or in the past, confirmed by HBV markers test.\n5. Anaphylaxis or severe allergy, or atopy, history of alcoholism or drug abuse.\n6. Pregnancy and breast-feeding.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Seroconversion Rate","description":"Percentage of subjects with an anti-HBs antibody level ≥ 2.1 mIU/mL 30 days after the last of three vaccinations. Seroconversion is defined as the development of a detectable anti-HBs antibody level above an established threshold of 2.1 mIU/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection Rate","description":"Percentage of subjects with an anti-HBs antibody level ≥ 10 mIU/mL prior to vaccination, 28 days after the first vaccination, 60 and 150 days after the second vaccination and 30 days after the third vaccination. The development of an anti-HBs antibody level of at least 10 mIU/mL is an established surrogate of seroprotection and correlate of protective immunity against HBV.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rate","description":"Percentage of subjects with an anti-HBs antibody level ≥ 2.1 mIU/mL prior to vaccination, 28 days after the first vaccination and 60 and 150 days after the second vaccination. Seroconversion is defined as the development of a detectable anti-HBs antibody level above an established threshold of 2.1 mIU/mL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMC) of HBs Antibodies","description":"Geometric mean concentration of anti-HBs antibody in mIU/mL 28 days after the first vaccination, 60 and 150 days after the second vaccination, and 30 days after the third vaccination.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"618.3","spread":"404.2"},{"groupId":"OG001","value":"378.7","spread":"417.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"757.7","spread":"378.0"},{"groupId":"OG001","value":"441.3","spread":"437.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"891.4","spread":"253.7"},{"groupId":"OG001","value":"787.0","spread":"351.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events: Local Reactions at the Injection Site- Incidence of Redness","description":"Incidence of mild erythema at the injection site 1, 2 and 28 days after the first vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events: Local Reactions at the Injection Site - Incidence of Itch","description":"Incidence of itchiness at the injection site at any point throughout the trial. Itchiness was assessed for 5 days following vaccinations on Days 1, 28, and 180 and also assessed on Day 90 and Day 210.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events: Local Reactions at the Injection Site - Incidence of Pain","description":"Incidence of pain at the injection site on the day of vaccination. Vaccination was performed on Day 1, Day 28, and Day 180.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Events: Local Reactions at the Injection Site - Intensity of Pain","description":"Pain was evaluated 30 minutes after each vaccination by the subject using the visual analogue scale. A higher score indicates greater pain intensity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["drowsiness","Hyperthermia","nausea","metallic taste","acute respiratory viral infection"]}}}